webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide

  CAS No.: 1226200-04-9   Cat No.: BADC-00553 4.5  

N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is an aldehyde-functionalized ADC linker that enables selective conjugation to antibodies, optimizing payload stability and targeted antibody-drug conjugate delivery.

N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide

Structure of 1226200-04-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C16H14ClNO3
Molecular Weight
303.74
Shipping
Room temperature

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
IUPAC Name
N-[2-(3-chlorophenoxy)ethyl]-4-formylbenzamide
Canonical SMILES
C1=CC(=CC(=C1)Cl)OCCNC(=O)C2=CC=C(C=C2)C=O
InChI
InChI=1S/C16H14ClNO3/c17-14-2-1-3-15(10-14)21-9-8-18-16(20)13-6-4-12(11-19)5-7-13/h1-7,10-11H,8-9H2,(H,18,20)
InChIKey
HHQGDMPWTIBYHU-UHFFFAOYSA-N
Shipping
Room temperature

N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide has attracted attention in the field of pharmaceutical research due to its distinct molecular structure and potential for various medical applications. The incorporation of both chlorophenoxy and formylbenzamide groups into its framework allows for unique interactions with biological targets, paving the way for its evaluation as a novel therapeutic agent. Scientists are particularly interested in exploring its effectiveness and safety across a range of diseases, offering hope for new treatment modalities that address both efficacy and safety challenges commonly faced in drug development.

One significant application of N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is in the realm of cancer therapeutics. Researchers are investigating its capability to act as an anti-cancer agent through mechanisms such as inhibition of cancer cell proliferation and induction of apoptosis. Its selective activity against malignant cells suggests it has the potential for development into a targeted therapy, which could result in fewer side effects compared to traditional chemotherapeutic agents. This focus on reducing collateral damage to healthy cells is critical in improving the quality of life for cancer patients and enhancing the overall effectiveness of cancer treatment regimens.

In addition to its potential in oncology, N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is being studied for its anti-inflammatory capabilities. Its structural properties allow it to modulate key inflammatory pathways, making it a promising candidate for the treatment of inflammatory conditions such as Crohn's disease and ulcerative colitis. By potentially reducing the overactive inflammatory responses that characterize these diseases, the compound could help alleviate symptoms and prevent long-term tissue damage. Researchers are actively conducting studies to better understand its mechanism of action and therapeutic potential in chronic inflammatory diseases.

Moreover, the compound holds promise in neurological applications, particularly in offering neuroprotection. Diseases like Alzheimer's and Parkinson's are characterized by progressive neuronal damage, and compounds that can protect nerve cells are of immense interest. N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide is being evaluated for its ability to support neuronal health and function, thereby possibly decelerating disease progression. The focus on neuroprotective properties is part of broader efforts to develop medications that not only manage symptoms but also address underlying disease mechanisms, potentially leading to breakthroughs in how neurodegenerative diseases are treated. This comprehensive approach highlights the compound's versatility and its importance in the pursuit of innovative therapies for complex diseases.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Mal-VC-PAB-PNP | Py-MPB-amino-C3-PBD | Mal-PEG8-NHS | MC-Val-Cit-PAB | Tetrazine-PEG4-SS-Py | Tetrazine-PEG4-oxyamine hydrochloride | DM4-SPDP | Tetrazine-PEG7-amine hydrochloride | Tetrazine-PEG5-SS-amine | Tetrazine-PEG4-amine hydrochloride | N-(2-(3-Chlorophenoxy)ethyl)-4-Formylbenzamide
Send Inquiry
Verification code
Inquiry Basket